Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nimotuzumab + nab-paclitaxel + gemcitabine
- Development stage
- Phase 2
- Lead developer
- Tianjin Medical University Cancer Institute and Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
nimotuzumab + nab-paclitaxel + gemcitabine is a combination chemo-immunotherapy regimen being investigated by the Tianjin Medical University Cancer Institute and Hospital for the treatment of locally advanced pancreatic cancer (LAPC). The regimen combines nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR), with the AG chemotherapy backbone consisting of nab-paclitaxel (albumin-bound paclitaxel) and gemcitabine. EGFR is frequently overexpressed in pancreatic tumors, making it a viable target for enhancing the efficacy of standard cytotoxic agents. In clinical study protocols, this combination is often administered as induction therapy followed by sequential irreversible electroporation (IRE) ablation, a non-thermal ablation technique intended to improve local disease control and overall survival in patients with unresectable disease.
- Other names
- Nimotuzumab + AGNimotuzumab + nab-paclitaxel + gemcitabineAG regimen + nimotuzumab
02
Targets
DNAEGFR (Epidermal growth factor receptor)RNR (Ribonucleotide reductase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on nimotuzumab + nab-paclitaxel + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nimotuzumab + nab-paclitaxel + gemcitabine.